Thermo Fisher Scientific Inc. (TMO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Thermo Fisher Scientific Inc. (TMO) Healthcare & Pipeline Overview

Thermo Fisher Scientific Inc. is a global leader providing a comprehensive suite of life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products. Serving diverse sectors like pharma, biotech, and healthcare, the company leverages its extensive portfolio and global reach to maintain a strong market position and drive innovation in scientific research and development.

What Is the Investment Thesis for TMO?

The company's focus on innovation and strategic acquisitions has enabled it to expand its product offerings and geographic reach. With a current P/E ratio of 31.71 and a profit margin of 15.2%, Thermo Fisher demonstrates financial stability and profitability. Key growth catalysts include increasing demand for biopharma services and expansion in emerging markets. However, potential risks include regulatory changes and increased competition. The company's beta of 0.97 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

TMO Key Highlights

Market capitalization of $225B reflects Thermo Fisher's dominant position in the life sciences and diagnostics industry.

• Profit margin of 15.2% indicates strong operational efficiency and pricing power.
• Gross margin of 39.4% demonstrates effective cost management in manufacturing and service delivery.
• Beta of 0.97 suggests lower volatility compared to the broader market, making it a relatively stable investment.
• Dividend yield of 0.37% provides a modest income stream for investors.

Who Are TMO's Competitors?

TMO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are TMO's Key Strengths?

Diversified product and service offerings.

• Strong global presence and market leadership.
• Proven track record of innovation and acquisitions.
• High customer retention due to integrated solutions.

What Are TMO's Weaknesses?

Exposure to regulatory changes and healthcare reforms.

• Dependence on research and development investments.
• Potential for product liability claims.
• Complexity of managing a large and diverse organization.

What Could Drive TMO Stock Higher?

Continued expansion of biopharma services through Patheon and PPD.

• Increasing demand for genetic sequencing technologies in clinical diagnostics.
• Potential for strategic acquisitions to expand product portfolio and market reach.
• Growth in emerging markets, particularly in Asia-Pacific.
• Advancements in personalized medicine driving demand for diagnostic tools.

What Are the Key Risks for TMO?

Rich valuation — a P/E of 31.71 runs well above the Healthcare sector’s ~21.60x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $4.7M recently.
• Regulatory changes and healthcare reforms affecting pricing and reimbursement.
• Economic downturns impacting research funding and capital spending.
• Intense competition from other life sciences companies.
• Technological disruptions rendering existing products obsolete.
• Intellectual property infringement and patent disputes.

What Are the Growth Opportunities for TMO?

• Expansion in Biopharma Services: Thermo Fisher has a significant opportunity to expand its biopharma services segment, particularly through its Patheon and PPD brands. The global biopharmaceutical market is projected to reach $526.45 billion by 2028, growing at a CAGR of 12.5% from 2021. By leveraging its integrated service offerings, Thermo Fisher can capture a larger share of this market, providing end-to-end solutions from drug development to commercialization. This expansion can be achieved through strategic partnerships and investments in advanced technologies.
• Growth in Emerging Markets: Expanding into emerging markets, particularly in Asia-Pacific, presents a substantial growth opportunity for Thermo Fisher. The increasing healthcare expenditure and growing research activities in countries like China and India drive demand for life sciences solutions and analytical instruments. By establishing a stronger presence in these regions through strategic acquisitions and partnerships, Thermo Fisher can tap into new revenue streams and diversify its geographic footprint. This expansion can significantly contribute to the company's long-term growth.
• Advancements in Genetic Sequencing: The increasing adoption of genetic sequencing technologies in clinical diagnostics and research offers a significant growth opportunity. The global genetic testing market is projected to reach $25.8 billion by 2027, growing at a CAGR of 11.4% from 2020. Thermo Fisher's Applied Biosystems and Invitrogen brands are well-positioned to capitalize on this trend by providing advanced sequencing platforms, reagents, and bioinformatics tools. Continued innovation in this area will drive revenue growth and strengthen the company's market leadership.
• Personalized Medicine: The rise of personalized medicine, which tailors medical treatment to the individual characteristics of each patient, presents a significant growth opportunity. Thermo Fisher's diagnostic and analytical tools are essential for identifying biomarkers and developing targeted therapies. By investing in research and development and collaborating with pharmaceutical companies, Thermo Fisher can play a key role in advancing personalized medicine and driving revenue growth. The personalized medicine market is expected to grow significantly over the next decade.
• Strategic Acquisitions: Thermo Fisher has a proven track record of successful acquisitions, which have expanded its product portfolio and market reach. Continuing to pursue strategic acquisitions in complementary areas, such as diagnostics and bioprocessing, will drive growth and enhance the company's competitive position. These acquisitions can provide access to new technologies, markets, and customer segments, contributing to long-term value creation. Thermo Fisher's strong financial position allows it to pursue these opportunities effectively.

What Are TMO's Competitive Advantages?

• Extensive product portfolio and integrated solutions.
• Strong brand recognition and reputation.
• Global reach and diversified revenue streams.
• High switching costs for customers due to integrated workflows.
• Proven track record of innovation and strategic acquisitions.

What Does TMO Do?

Founded in 1956 and headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. has evolved into a global leader in serving science. The company provides a comprehensive range of products and services, including life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services. Thermo Fisher operates through four main segments: Life Sciences Solutions, which offers reagents, instruments, and consumables for biological and medical research; Analytical Instruments, providing instruments, software, and services for various research and industrial markets; Specialty Diagnostics, offering diagnostic reagent kits and blood test systems; and Laboratory Products and Biopharma Services, providing laboratory products and clinical research services. The company's products and services are sold through a direct sales force, customer service professionals, electronic commerce, and third-party distributors under brands like Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. With a global presence spanning North America, Europe, and Asia-Pacific, Thermo Fisher supports a wide array of customers across the pharmaceutical, biotechnology, healthcare, academic, and government sectors.

What Products and Services Does TMO Offer?

• Provide life sciences solutions for biological and medical research.
• Offer analytical instruments for pharmaceutical, biotechnology, and environmental markets.
• Develop and market specialty diagnostics for clinical diagnosis and monitoring.
• Manufacture and distribute laboratory products for research and safety.
• Provide biopharma services, including drug development and clinical research.
• Offer reagents, instruments, and consumables for drug and vaccine production.
• Provide complete blood test systems for allergy, asthma, and autoimmune diseases.
• Offer human leukocyte antigen typing and testing for organ transplant market.

How Does TMO Make Money?

• Develop, manufacture, and sell a wide range of life sciences products and services.
• Generate revenue through direct sales, customer service professionals, and electronic commerce.
• Utilize third-party distributors to expand market reach.
• Offer integrated solutions combining products, services, and software.
• Focus on innovation and strategic acquisitions to drive growth.

What Industry Does TMO Operate In?

Thermo Fisher Scientific operates in the medical diagnostics and research industry, which is experiencing growth driven by advancements in biotechnology, increasing healthcare expenditure, and the rising prevalence of chronic diseases. The industry is characterized by intense competition and rapid technological advancements. Thermo Fisher's diversified portfolio, global reach, and strong brand recognition position it favorably against competitors like AstraZeneca PLC (AZN), Novartis AG (NVS), and Merck & Co., Inc. (MRK). The company's focus on innovation and strategic acquisitions allows it to stay ahead of market trends and maintain its competitive edge.

Who Are TMO's Key Customers?

• Pharmaceutical and biotechnology companies.
• Academic and research institutions.
• Government agencies.
• Clinical laboratories.
• Healthcare providers.

Company Profile

Thermo Fisher Scientific Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Marc N. Casper. TMO has traded publicly since 1980.

Thermo Fisher Scientific Inc. Financial Trajectory

Thermo Fisher Scientific Inc. (TMO) reported $11.99B in revenue for Q2 FY2026, reflecting 9.0% growth compared to the prior quarter. The company recorded net income of $1.74B, with diluted EPS of $4.68. Quarter-over-quarter revenue has been mixed, typical for a mega-cap company operating in Healthcare. Across the four most recent quarters, TMO averaged $4.65 in diluted EPS.

How Thermo Fisher Scientific Inc. Is Valued

Thermo Fisher Scientific Inc. carries a market capitalization of $225B, placing it in the mega-cap category. Analyst price targets span from $520.00 to $650.00, with a consensus of $597.67. At the current price of $605.98, that implies roughly 1% downside from the consensus target. Relative to its peer group, TMO's quantitative score of 64/100 is roughly in line with the peer average of 71/100.

Return on equity for Thermo Fisher Scientific Inc. stands at 13.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.2%, showing how much profit it generates from its asset base. TMO trades at a trailing price-to-earnings ratio of 31.71, above the Healthcare sector average of ~21.60x. Its free cash flow yield is 3.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.2%, the inverse of the P/E and a quick read on earnings relative to price.

Thermo Fisher Scientific Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.79 places it in the safe zone, indicating low near-term bankruptcy risk.

Thermo Fisher Scientific Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 2.9% above estimates on average.

Over the past six months, Thermo Fisher Scientific Inc. insiders filed 30 SEC Form 4 transactions — 28 sales and 2 purchases. On net that is roughly 7K shares disposed (about $4.7M), a signal worth weighing alongside the fundamentals.

TMO Financials

TMO earnings history & estimates →

TMO Latest News

TMO Analyst Consensus

TMO MoonshotScore

Latest Thermo Fisher Scientific Inc. Analysis

Common Questions About TMO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources